Welcome to the Radiopharmaceutical Education Institute

In this introductory address, Oliver Sartor, MD, introduces the new Radiopharmaceutical Education Institute (RPEI), a platform designed to equip clinicians with the insight and evidence needed to inform treatment decisions and shape the future of radiopharmaceutical innovation in cancer care. He reflects on the rapidly expanding role of radiopharmaceutical therapy and theranostics in oncology and the growing need for thoughtful clinical integration as these therapies move across multiple disease states.

As innovation accelerates, clinicians face increasingly complex decisions around patient selection, sequencing, and multidisciplinary coordination. RPEI was established to advance the science and clinical integration of radiopharmaceutical therapies through expert-driven education and cross-specialty dialogue, supporting informed decision-making and responsible advancement in modern cancer care.

Transcript:

Hi, I'm Dr. Oliver Sartor. I'm the Director of the LCMC Health Transformational Prostate Cancer Center in New Orleans, Louisiana. I'm pleased to welcome you to the Radiopharmaceutical Education Institute. 

I think we all know that radiopharmaceuticals are entering a pivotal moment in oncology. Over the past several years, we've seen remarkable advances in radioligand therapy and theranostics across many different cancers. What was once considered a niche area of nuclear medicine is now becoming a functional modality in modern cancer care. 

The pace of innovation is accelerating. We're having new targets, new isotopes, earlier line studies, combination strategies, and all of these are under active investigation. It's an exciting area for our field. The challenge is rapid innovation brings complexity. Without a doubt, we have to understand patient selection, sequencing, collaborations between oncology and nuclear medicine. And in order to be able to bring these treatments into broader practice settings, we're going to have to ask as clinicians a number of important questions.

• How do we interpret the emerging trial data? 
• How do we integrate these therapies responsibly into treatment algorithms? 
• How do we coordinate effectively across specialties? 

Education sometimes does not keep pace with therapeutic advancement, and that's where RPEI comes in. The Radiopharmaceutical Education Institute, or RPEI, was created to provide rigorous, multidisciplinary, education-based research that is evidence-based across the radiopharmaceutical therapies. Our goal is to bridge oncology and nuclear medicine, bringing together perspectives from across disciplines to support clinical decision-making. 

The platform is designed to offer thoughtful interpretation of clinical data, foundational education on theranostics, and forward-looking discussions about where the field is headed. 

As an editorial advisor, I'm particularly excited about fostering a balanced dialogue, ensuring that we approach this with scientific rigor and enthusiasm. Looking ahead, we're no longer in radiopharmaceuticals considered an emerging therapy. They're central to how we treat certain cancers, and this will expand in the years ahead.

As new evidence emerges and new indications develop, it's essential we remain grounded in science, collaborative with our colleagues, and thoughtful in how we integrate these therapies into practice. I invite you to explore the educational resources within RPEI and to engage with the multidisciplinary insights shared by colleagues across the field. Together, we can help ensure that radiopharmaceutical innovation translates into meaningful, responsible advances in patient care. 

Thank you for joining us.